Pushing Boundaries in API Synthesis: Our Journey to Elevate Clazosentan Production Featured in OPR&D Publication

We are delighted to share a breakthrough in our API synthesis processes that promises to transform the production of Clazosentan, a flagship drug in the Japanese market.  Idorsia and CARBOGEN AMCIS collaborated to develop a groundbreaking route for synthesizing 5-Methyl-2-pyridinesulfonamide (M001300), a critical API starting material for Clazosentan production.

This accomplishment has been recognized and detailed in the Organic Process Research & Development (OPR&D) journal. We invite you to delve into the comprehensive publication, which chronicles the intricate journey of this synthesis process.

At CARBOGEN AMCIS, our unwavering commitment to pioneering excellence propels us to continuously redefine the boundaries of possibility. We extend our heartfelt gratitude to all contributors who have played a role in this remarkable achievement.